RxDoctor Payments Data

Francesco Vendrame, MD

Endocrinology, Diabetes & Metabolism · Miami, FLNPI 1093119554

Payments from drug & device makers

$79,224in general payments, 2019–2025

Across 22 payments — averaging $3601.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$75K
  • Eli Lilly$4K
  • Mannkind Corporation$59
  • AstraZeneca$30
  • Insulet Corporation$26
  • Merck$16
  • plus $37 from 3 others

What the payments were for

  • Consulting fees$4,00096%
  • Food & beverage$972%
  • Education$120%
  • Gifts$591%

General payments by program year

19
20
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$79,224 in reported general payments places this provider in the 85th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

See all endocrinology, diabetes & metabolism providers in Florida

Medicare billing

Part B allowed, 2024
$38,681
Medicare patients
162
Services billed
413

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide350$503,107
TrulicityDulaglutide142$235,095
JardianceEmpagliflozin125$183,129
MounjaroTirzepatide77$119,886
Tresiba Flextouch U-100Insulin Degludec64$58,598
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/739$41,358
FarxigaDapagliflozin Propanediol27$38,511
Fiasp FlextouchInsulin Aspart (Niacinamide)27$33,930
JanuviaSitagliptin Phosphate40$29,516
Budesonide ErBudesonide12$27,830
Novolog FlexpenInsulin Aspart60$21,957
BaqsimiGlucagon44$19,396
Lantus SolostarInsulin Glargine,hum.Rec.Anlog118$17,362
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog34$15,427
NovologInsulin Aspart36$13,073

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Baqsimi, Humalog, Humulin 70-30$12$383,132295 claims
AstraZenecaFarxiga$30$38,51127 claims
MerckJanuvia$16$29,51640 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

Other endocrinology, diabetes & metabolism in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →